ΔΙΑΣΠΕΙΡΟΜΕΝΟΙ ΝΑΝΟΚΡΥΣΤΑΛΛΟΙ ΣΙΛΔΕΝΑΦΙΛΗΣ | ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΕΠΙΣΤΗΜΟΝΙΚΑ ΠΕΡΙΟΔΙΚΑ - ΔΡΑΣΕΙΣ ΔΙΑΧΥΣΗΣ Τ2ΕΔΚ-00540

Συγγραφείς
Ioannis Mykoniatis, Nikolaos Pyrgidis, Ioannis Sokolakis, Andreas Ouranidis, Petros Sountoulides, Anna-Bettina Haidich, Koenraad van Renterghem, Georgios Hatzichristodoulou, Dimitrios Hatzichristou
Ημερομηνία δημοσίευσης
2021/2/1
Πηγή
JAMA network open
Τόμος
4
Τεύχος
2
Σελίδες
e2036337-e2036337
Εκδότης
American Medical Association
Περιγραφή

Importance

Combining 2 first-line treatments for erectile dysfunction (ED) or initiating other modalities in addition to a first-line therapy may produce beneficial outcomes.

Objective

To assess whether different ED combination therapies were associated with improved outcomes compared with first-line ED monotherapy in various subgroups of patients with ED.

Data Sources

Studies were identified through a systematic search in MEDLINE, Cochrane Library, and Scopus from inception of these databases to October 10, 2020.
 
Συγγραφείς
Andreas Ouranidis, Anastasia Tsiaxerli, Elisavet Vardaka, Catherine K Markopoulou, Constantinos K Zacharis, Ioannis Nicolaou, Dimitris Hatzichristou, Anna-Bettina Haidich, Nikolaos Kostomitsopoulos, Kyriakos Kachrimanis
Ημερομηνία δημοσίευσης
2021/4/15
Πηγή
Pharmaceuticals
Τόμος
14
Τεύχος
4
Σελίδες
365
Εκδότης
MDPI
Περιγραφή
Sildenafil is a potent selective, reversible inhibitor of phosphodiesterase type 5 (PDE5) approved for the treatment of erectile dysfunction and pulmonary arterial hypertension. Whilst twenty years have passed since its original approval by the US Food and Drug Administration (USFDA), sildenafil enters the fourth industrial era catalyzing the treatment advances against erectile dysfunction and pulmonary hypertension. The plethora of detailed clinical data accumulated and the two sildenafil analogues marketed, namely tadalafil and vardenafil, signify the relevant therapeutic and commercial achievements. The pharmacokinetic and pharmacodynamic behavior of the drug appears complex, interdependent and of critical importance whereas the treatment of special population cohorts is considered. The diversity of the available formulation strategies and their compatible administration routes, extend from tablets to bolus suspensions and from per os to intravenous, respectively, inheriting the associated strengths and weaknesses. In this comprehensive review, we attempt to elucidate the multi-disciplinary elements spanning the knowledge fields of chemical synthesis, physicochemical properties, pharmacology, clinical applications, biopharmaceutical profile, formulation approaches for different routes of administration and analytical strategies, currently employed to guide the development of sildenafil-based compositions.
 
 
Συγγραφείς
Nikolaos Pyrgidis, Ioannis Mykoniatis, Anna-Bettina Haidich, Maria Tirta, Persefoni Talimtzi, Dimitrios Kalyvianakis, Andreas Ouranidis, Dimitrios Hatzichristou
Ημερομηνία δημοσίευσης
2021
Πηγή
Frontiers in pharmacology
Σελίδες
2410
Εκδότης
Frontiers
Περιγραφή

Background:

 
Multiple systematic reviews explore the effect of phosphodiesterase type 5 (PDE5) inhibitors on erectile dysfunction (ED), with each study addressing specific outcomes. However, physicians and policymakers require a holistic approach of this topic.

Objective:

 
To summarize the current evidence regarding the efficacy and safety of PDE5 inhibitors for the management of ED through an overview of systematic reviews.
 
 
 
Συγγραφείς
Andreas Ouranidis, Christina Davidopoulou, Kyriakos Kachrimanis
Ημερομηνία δημοσίευσης
2021/10/22
Επιστημονικό άρθρο
Pharmaceutics
Τόμος
13
Τεύχος
11
Σελίδες
1771
Εκδότης
MDPI
Περιγραφή
Comminution of BCS II APIs below the 1 μm threshold followed by solidification of the obtained nanosuspensions improves their dissolution properties. The breakage process reveals new crystal faces, thus creating altered crystal habits of improved wettability, facilitated by the adsorption of stabilizing polymers. However, process-induced transformations remain unpredictable, mirroring the current limitations of our atomistic level of understanding. Moreover, conventional equations of estimating dissolution, such as Noyes–Whitney and Nernst–Brunner, are not suitable to quantify the solubility enhancement due to the nanoparticle formation; hence, neither the complex stabilizer contribution nor the adsorption influence on the interfacial tension occurring between the water and APIs is accounted for. For such ternary mixtures, no numeric method exists to correlate the mechanical properties with the interfacial energy, capable of informing the key process parameters and the thermodynamic stability assessment of nanosuspensions. In this work, an elastic tensor analysis was performed to quantify the API stability during process implementation. Moreover, a novel thermodynamic model, described by the stabilizer-coated nanoparticle Gibbs energy anisotropic minimization, was structured to predict the material’s system solubility quantified by the application of PC-SAFT modeling. Comprehensively merging elastic tensor and PC-SAFT analysis into the systems-based Pharma 4.0 algorithm provided a validated, multi-level, built-in method capable of predicting the critical material quality attributes and corresponding key process parameters.